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ABSTRACT
The knowledge on how tumor-associated stroma influences efficacy of anti-cancer 
therapy just started to emerge. Here we show that lung fibroblasts reduce melanoma 
sensitivity to the BRAF inhibitor (BRAFi) vemurafenib only if the two cell types are in 
close proximity. In the presence of fibroblasts, the adjacent melanoma cells acquire 
de-differentiated mesenchymal-like phenotype. Upon treatment with BRAFi, such 
melanoma cells maintain high levels of phospho ribosomal protein S6 (pS6), i.e. active 
mTOR signaling, which is suppressed in the BRAFi sensitive cells without stromal 
contacts. Inhibitors of PI3K/mTOR in combination with BRAFi eradicate pS6high cell 
subpopulations and potentiate anti-cancer effects in melanoma protected by the 
fibroblasts. mTOR and BRAF co-inhibition also delayed the development of early-stage 
lung metastases in vivo. In conclusion, we demonstrate that upon influence from 
fibroblasts, melanoma cells undergo a phenotype switch to the mesenchymal state, 
which can support PI3K/mTOR signaling. The lost sensitivity to BRAFi in such cells 
can be overcome by co-targeting PI3K/mTOR. This knowledge could be explored for 
designing BRAFi combination therapies aiming to eliminate both stroma-protected 
and non-protected counterparts of metastases.
INTRODUCTION
The role of stromal cells in facilitating metastasis 
and drug-resistance is becoming increasingly recognized 
[1, 2]. A variety of stromal cells (fibroblasts, endothelial 
cells and myeloid cells) can reduce cancer cells’ sensitivity 
to chemotherapy [3–7], and particularly targeted therapy 
[3]. This effect has been linked to stroma-secreted soluble 
factors [3, 4, 8], cell-cell junctions [9, 10] or deposition of 
extracellular matrix (ECM) [11, 12] that can activate pro-
survival mechanisms in the cancer cells. Besides, stromal 
cells can promote epithelial-mesenchymal transition 
(EMT), a phenomenon when epithelial cancer cells 
acquire a motile mesenchymal phenotype [13]. It appears 
that cancer cells with mesenchymal features often show 
higher resistance to therapies [14, 15]. Thus, phenotype 
plasticity has been suggested as an important mechanism 
of drug-resistance and a potential target for therapy [16].
Malignant melanoma is one of the most aggressive, 
drug-resistant cancer types with a median survival of 
stage IV patients of 8-18 months [17]. Until recently, 
effective therapies against metastatic melanoma were 
lacking. However, significant progress has been achieved 
with inhibitors targeting frequently mutated BRAF [18]. 
Mutant BRAF constitutively activates the downstream 
kinases, MEK and ERK, within the mitogen-activated 
protein kinase (MAPK) pathway, leading to uncontrolled 
cell proliferation. BRAF inhibitors (BRAFi), like 
vemurafenib, suppress MAPK and often induce tumor 
regression. However, there is variability in the magnitude 
of the initial response, and resistance usually develops 
within one year [19]. A number of acquired resistance 
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mechanisms have been disclosed, including re-activation 
of MAPK [20–22] and activation of alternative signaling 
pathways, such as the phosphatidylinositol 3-kinase 
(PI3K) cascade [20, 23]. It has also been observed that 
melanomas with a mesenchymal gene signature, i.e. 
reduced expression of melanocytic genes and enhanced 
expression of mesenchymal genes, are more resistant 
to BRAFi [24–26]. Furthermore, it has been shown that 
BRAFi resistance could be promoted by growth factors 
secreted by stromal cells [3, 8].
Revealing factors affecting sensitivity to BRAFi 
is important in the search of biomarkers of response, 
or combination therapies involving BRAFi. It has been 
shown that BRAFi-induced suppression of a mammalian 
target of rapamycin complex 1 (mTORC1) is associated 
with a good BRAFi response, while a maintained 
mTORC1 activity predicts BRAFi resistance [27]. 
Typically, mTORC1 is activated via the PI3K/AKT 
pathway [28], but MAPK-dependent activation has 
also been observed [29, 30]. Since mTORC1 converges 
both signaling cascades, mTORC1 activity-reflecting 
substrates could be good indicators of BRAFi response/
resistance [27, 30]. One such substrate is phospho 
ribosomal protein S6 (pS6) that has been proposed as 
a biomarker for assessing the effectiveness of BRAF-
targeted therapies [27, 31].
Here we show that stromal cells, such as lung 
fibroblasts, reduce melanoma sensitivity to BRAFi and 
lead to emergence of non-responding cell subpopulations 
with high levels of pS6. Stroma-mediated protection was 
dependent on close proximity between the two cell types, 
which resulted in phenotype switching and signaling re-
wiring in melanoma. These findings place stromal cells 
as important contributors to BRAFi resistance and reveal 
candidates for targeting stroma-protected parts of the tumor.
RESULTS
Melanoma cells in mono-cultures show good 
response to BRAFi
In this study we applied four BRAF-mutated 
melanoma cell lines derived from lymph node or brain 
metastases and stably labeled with GFP-luciferase (further 
referred as Luc+). Cell sensitivity to the BRAF inhibitor 
vemurafenib was scored by measuring bioluminescence 
generated by viable luciferase-expressing cells. The 
method was described previously [6] and further 
validated in our cell system (Supplementary Figure S1). 
All tested cell lines showed good response to BRAFi, 
where half-maximal effective concentrations (EC50) 
were below 1μM (Figure 1A). At the molecular level, 
we observed a decrease in phosphorylation of ERK and 
S6 (Figure 1B), markers of the MAPK and mTORC1 
activity, respectively. Altogether, this indicates that the 
four melanoma cell lines, when grown as mono-cultures, 
are highly sensitive to BRAFi.
Stromal cells protect melanoma cells from 
BRAFi via proximity-dependent interactions
To evaluate stromal influence on melanoma 
response to BRAFi, the Luc+ melanoma cells were 
grown together with Luc- lung fibroblasts WI-38 as co-
cultures, where the cells are in close proximity to each 
other. The response to BRAFi was evaluated by measuring 
bioluminescence produced exclusively by Luc+ tumor 
cells. All four melanoma cell lines showed improved cell 
survival/growth and significantly increased EC50 when 
treated in the co-culture conditions compared to the mono-
culture (Figure 2A, 2B) (no effect on the fibroblasts was 
observed). In concordance, the level of the proliferation 
marker Ki-67 stayed high in the treated co-cultures, 
while it was significantly reduced by BRAFi in the 
mono-cultures (Figure 2C). Altogether, this indicates that 
fibroblasts reduce melanoma sensitivity to BRAFi. Since 
fibroblasts deposit fibronectin, which can diminish BRAFi 
efficacy [11, 12], we also evaluated melanoma sensitivity 
to BRAFi on the fibronectin-coated (5μg/cm2) surface. 
Although we observed increased cell survival/growth upon 
treatment on fibronectin, the protective effect was lower 
than what was seen in the co-cultures (data not shown). 
This suggests that adhesion to fibronectin can contribute, 
but is not the sole mechanism of the fibroblast-mediated 
protection from BRAFi.
To examine the influence of other types of stromal 
cells, we co-cultured Melmet 5 with endothelial cells 
HUVEC or monocytes THP-1. Endothelial cells, like 
fibroblasts, adhered to melanoma cells and elicited 
protection from BRAFi (Figure 3A, left). No adhesion was 
observed between melanoma cells and monocytes, and the 
monocytes did not confer any protective influence (Figure 
3A, right).
To validate the importance of the tumor-stromal 
cell proximity/adhesion for the protection, we generated 
cultures where the cell proximity was disabled by a semi-
permeable membrane. Melanoma cells were grown on 
semi-permeable inserts, whereas fibroblasts were grown 
on the bottom of a trans-well chamber. This prevents cell-
cell adhesion, but allows communication through soluble 
factors. In contrast to the co-cultures, we did not observe 
fibroblast-induced protection from BRAFi in Melmet 5 or 
HM8 grown on the inserts (Figure 3B).
Protective stroma alters the molecular phenotype 
of the melanoma cells
To investigate changes in the molecular profile of 
melanoma, GFP+ Melmet 5 cells from mono-cultures and 
co-cultures with GFP- fibroblasts, with/without BRAFi 
treatment, were separated by fluorescence-activated cell 
sorting (FACS) and analyzed for global gene expression. 
Principle component analysis (PCA) on normalized data 
projects variance between the four sample groups. It 
shows much greater expression differences induced by 
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BRAFi in the mono-cultures than the co-cultures (Figure 
4A): 742 versus 34 modulated genes, respectively. This 
indicates a dampened transcriptional response to BRAFi 
in the melanoma cells in the co-cultures.
Also in the absence of the drug, a clear gene 
expression variance (608 differentially expressed genes) 
was observed between the melanoma cells from the co-
cultures versus the mono-cultures (Figure 4A). This 
indicates a significantly altered transcriptional profile 
of melanoma cells due to contact with fibroblasts. The 
transcriptional signatures of the untreated Melmet 5 cells 
isolated from the co-cultures versus the mono-cultures are 
compared in Figure 4B. A cluster of the down-regulated 
genes harbors a number of melanocyte differentiation 
genes controlled by the master regulator of the lineage, 
microphthalmia-associated transcription factor MITF. In 
the up-regulated gene cluster we found genes characteristic 
for the mesenchymal/invasive phenotype defined 
previously by others [32, 33]. q-PCR was performed to 
validate the fibroblast-induced transcriptional changes 
in selected differentiation genes (MITF, TYR and 
MLANA), and the mesenchymal signature genes (AXL, 
Figure 1: Melanoma cells grown as mono-cultures show good response to BRAFi. A. Four different melanoma cell lines 
grown as mono-cultures were treated with different doses of BRAFi for 72 h before the effect on melanoma cells was scored by measuring 
bioluminescence. The signal intensity in the treated cells was related to the intensity in the non-treated controls and presented in % (average 
± SEM, n ≥ 3). B. Western blot analysis of the levels of the indicated proteins (α-tubulin, as a loading control) in non-treated or treated 
(with 1 μM BRAFi for 24 h) melanoma cells.
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THBS1, DKK3) in Melmet 5 (Figure 4C) and HM8 
(Supplementary Figure S2A). No significant changes 
in the expression of all these genes were observed in 
melanoma cells separated from the fibroblasts by semi-
permeable inserts (Supplementary Figure S2B and S2C).
To reveal alterations in the proteome, the FACS-
isolated melanoma cells were analyzed by reverse-
phase protein array (RPPA). Like the transcriptome, 
the proteome was significantly altered in the untreated 
melanoma cells from the co-cultures compared to the 
mono-cultures. Figure 4D shows the proteins that were 
most up-regulated in Melmet 5 cells from the co-cultures, 
confirming an enrichment for Axl and other mesenchymal 
proteins, such as PDGFRB, fibronectin and vimentin. The 
same proteins were found to be enriched also in HM8 cells 
from the co-cultures (data not shown). To note, the purity 
of the melanoma fractions was carefully validated (see 
Materials and Methods) to exclude a possibility that the 
observed mesenchymal signature is due to contamination 
with fibroblasts. In summary, gene/protein profiling 
Figure 2: Melanoma cells co-cultured with lung fibroblasts are more resistant to BRAFi. A. Four different melanoma 
cell lines were grown as mono-cultures or co-cultures with lung fibroblasts WI-38 with/without BRAFi treatment for 72 h. The effect on 
melanoma cells was scored by measuring bioluminescence and is presented as % relative to the respective non-treated controls (average 
± SEM, n ≥ 3); *, p ≤ 0.05 at all doses (unpaired t-test). B. BRAFi EC50 values for each cell line treated in the mono-culture or co-culture 
conditions. C. The level of Ki-67 (detected by flow cytometry) in melanoma cells grown as mono-cultures or co-cultures and treated with 
1 μM BRAFi for 72 h. The levels in the non-treated controls are shown for comparison.
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revealed that in the presence of adjacent fibroblasts, the 
melanoma cells undergo phenotype switching to the de-
differentiated mesenchymal state.
Protective stroma enables BRAFi-treated 
melanoma to maintain high levels of pS6 and cell 
cycle progression
As reported previously, low levels of MITF and 
high levels of AXL may predict melanoma resistance 
to BRAFi [24, 26], and the resistance may involve 
(re)activation of MAPK [20, 22] or PI3K/mTOR signaling 
[23, 27]. To assess MAPK activity, the melanoma cells 
from the mono-cultures and the co-cultures were analyzed 
for pERK by flow cytometry. We detected BRAFi-induced 
suppression of pERK in both culture conditions (Figure 
5A). The same was seen by immunofluorescence, where 
after BRAFi we observed green melanoma cells with 
low signal of pERK in red (Figure 5B). In the treated co-
cultures, though, some single melanoma cells retained 
ERK phosphorylation (seen as yellow, Figure 5B). In 
conclusion, generally, we observed pERK suppression 
by BRAFi in both the mono-cultures and the co-cultures. 
However, more sensitive methods are needed to quantify 
whether there is a difference in the suppression magnitude.
To compare levels of PI3K/AKT/mTOR-associated 
proteins in the mono-cultures and the co-cultures, 
phosphorylated AKT, GSK-3β, S6 and mTOR were 
analyzed in FACS-separated melanoma cells by Western 
blotting and/or Simple Western immunoassay. We 
observed only minor alterations in pAKT levels. However, 
the phosphorylation of an AKT substrate, GSK-3β, and 
particularly an mTOR substrate, S6, as well as mTOR 
itself was significantly reduced by BRAFi in the mono-
cultures but not in the co-cultures with fibroblasts (Figure 
6A, 6B and Supplementary Figure S3A-C). To note, 
S6 phosphorylation at positions S235/236 (that can be 
regulated by MAPK in addition to mTOR) and S240/244 
Figure 3: Melanoma cell sensitivity to BRAFi in the presence of endothelial cells, monocytes or fibroblasts separated by 
a semi-permeable membrane. A. Melanoma cells were grown either as mono-cultures or co-cultures with endothelial cells HUVEC 
or monocytes THP-1. B. Melanoma cells were grown on semi-permeable inserts, where the fibroblasts or the respective melanoma cells 
(“No fibroblasts”= Controls) were grown in the bottom chamber. Cells were treated with different doses of BRAFi for 72 h before the drug 
effect was scored by bioluminescence (A) or the MTS (B) method. The effect on melanoma cells is presented as % relative to the respective 
non-treated controls (average ± SEM, n ≥ 3); *, p ≤ 0.05 at doses ≥ 1 μM (unpaired t-test).
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Figure 4: Fibroblasts induce global gene expression changes in melanoma cells. Melmet 5 melanoma cells, grown either 
as mono-cultures or co-cultures with fibroblasts were treated with 1 μM BRAFi for 24 h (controls were not treated), isolated by FACS 
and analyzed for gene expression (A-C) or protein levels (D). A. A PCA plot showing the variance between four groups (3 sets): non-
treated mono-cultures (Mono) and co-cultures (Co), and BRAFi-treated mono-cultures (Mono+BRAFi) and co-cultures (Co+BRAFi). B. A 
heatmap showing gene expression levels in melanoma cells from co- versus mono-cultures (n=3). The scale bar indicates signal intensity, 
where green and red colors indicate low and high expression, respectively. Gene names labeled in green denote differentiation signature 
genes, while genes in red denote invasive/mesenchymal signature genes reported previously [32, 33]. C. Relative gene expression of 
differentiation and mesenchymal signature genes, detected by q-PCR (average ± SEM, n=3); *, p < 0.05. The expression level in the co-
cultures was normalized to the level in the mono-cultures set to 1. Insert: MITF and AXL expression changes were confirmed by Western 
blotting (histone 3 (H3) as a loading control). D. A heatmap from the RPPA analysis that shows significantly enriched (at least by 20%) 
proteins in the melanoma cells from the co-cultures versus the mono-cultures (n=3). Proteins are ranked based on fold-enrichment, with 
the most enriched at the top.
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(regulated predominantly by mTOR [34]) showed the 
same pattern of changes (Supplementary Figure S4). 
Taken together, this indicates a lack of mTOR suppression 
by BRAFi in the co-cultures. To note, when melanoma-
fibroblast contact was prevented by semi-permeable 
inserts, or when melanoma cells were co-cultured together 
with monocytes, the level of pS6 was significantly reduced 
by BRAFi (Figure 6C). This supports the importance of 
tumor-stroma proximity for sustaining mTOR activity in 
BRAFi-treated melanoma.
To explore pS6 levels in single melanoma cells, we 
employed flow cytometry. The data confirms a BRAFi-
induced decrease in pS6 in mono-cultures, which was 
shown for different drug doses, cell densities or treatment 
durations (Supplementary Figure S5A-C). In contrast, in 
the co-cultures with fibroblasts, the level of pS6 remained 
significantly higher (Figure 7A) and stayed so for the 
whole treatment duration for up to 3 days (Supplementary 
Figure S5C). Importantly, in the treated co-cultures we 
discriminated two melanoma cell subpopulations: those 
with a reduced pS6 level, and those with high levels, like 
in controls (Figure 7A). These two subpopulations had 
a clearly different cell cycle profile: pS6low cells were 
arrested in G1, while pS6high cells mimicked the untreated 
Figure 5: The level of pERK in BRAFi treated melanoma cells from mono-cultures or co-cultures with fibroblasts. 
Melanoma cells were grown as mono-cultures or co-cultures with fibroblasts and treated with 1 μM BRAFi for 24 h (controls were not 
treated) before analysis for pERK by flow cytometry (A) or immunofluorescence (B). A. pERK median level in treated melanoma cells 
relative to the level in the respective non-treated controls (set to 100) is shown. Data indicates average ± SEM, n≥3; *, p< 0.05 (unpaired 
t-test). Lower panel: representative histograms indicating pERK levels in single melanoma cells. B. The cultures were immunostained for 
pERK (red) and GFP (green); cell nuclei were stained with DAPI. Only overlay pictures are shown (enlarged region indicated). Scale bar, 
50 μm.
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controls with cell cycle distribution in G1/S/G2 (Figure 
7B). This indicates that the pS6 level discriminates 
BRAFi-responders that stop progression through a cell 
cycle, from non-responders that continue cycling.
To verify the stromal role in maintenance of pS6 
after BRAFi, we analyzed asymmetric co-cultures, 
where melanoma culture regions and fibroblast culture 
regions were allowed to invade each other, forming 
an interaction front as illustrated in Figure 8. In the 
interaction front, the green melanoma cells displayed 
an elongated mesenchymal morphology which was not 
observed in the melanoma cells at the distant site (Figure 
8, GFP). The level of pS6 in the melanoma cells in the 
interaction front versus the distant sites was compared. In 
the absence of BRAFi, all melanoma cells, regardless of 
their localization, had high levels of red-stained pS6 (seen 
as orange cells in the overlay picture). In the presence of 
BRAFi, the melanoma cells in the interaction front stayed 
strongly positive for pS6. In contrast, a large fraction of 
the melanoma cells in the distant site lost the red pS6 
Figure 6: The level of PI3K/AKT/mTOR signaling-associated proteins in BRAFi-treated melanoma cells with/without 
stromal cells present. A, B. Melanoma cells were grown as mono-cultures or co-cultures with fibroblasts, treated with 1 μM BRAFi 
for 24 h (controls were not treated), isolated by FACS and analyzed for the indicated proteins by Western blotting (α-tubulin as a loading 
control) (A) or automated Simple Western (B). (B) p-mTOR level (after normalization to the loading control, GAPDH) in the treated cells 
relative to the respective non-treated controls (set to 100). Average ± SEM (n=3 for Melmet 5; n=1 for HM8); *, p< 0.05 by unpaired t-test. 
C. Western blot analysis of pS6 in melanoma cells grown/treated on semi-permeable inserts with/without fibroblasts in the bottom chamber 
or as co-cultures in the presence of monocytes THP-1.
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signal and appeared green in the overlay picture. Such 
heterogeneous behavior was observed in both models, 
HM8 (Figure 8) and Melmet 5 (data not shown). This 
confirms that fibroblasts make adjacent melanoma cells 
acquire mesenchymal features and sustain pS6 levels upon 
treatment with BRAFi.
Exploring pS6 in melanoma cells from distinct 
sites in vivo
The observation that fibroblasts foster melanoma 
cell subpopulations with sustained pS6 levels, motivated 
in vivo studies where we compared the influence of stroma 
from different sites. Melmet 5 cells establish tumors in 
multiple organs when injected into mice through the 
left ventricle (L.V.), or grown subcutaneously after 
subcutaneous (s.c.) injection, thereby generating distinct 
interactions with site-specific stroma. The metastatic 
cells from different sites of non-treated and BRAFi-
treated animals were isolated and analyzed for pS6 by 
flow cytometry. We observed cellular heterogeneity with 
respect to the pS6 level, where only a fraction of the 
melanoma cells were strongly positive for pS6 (pS6high) 
(Figure 9). After BRAFi treatment, the percentage of 
Figure 7: Flow cytometric analysis of pS6 levels and cell cycle in melanoma cells from mono-cultures and co-cultures 
with fibroblasts. Melanoma cells were grown as mono-cultures or co-cultures with fibroblasts, treated with 1 μM BRAFi for 24 h 
(controls were not treated) before the total cell suspension was analyzed for pS6 levels (A) and cell cycle (B). A. Representative histograms 
indicating pS6 levels in single melanoma cells; dotted lines designate the histogram peak position in the non-treated cells. B. DNA content 
(i.e. cell cycle distribution) in non-treated and BRAFi treated melanoma cells from the co-cultures, where the latter were divided into 
subpopulations with low (pS6low) and high (pS6high) levels of pS6.
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pS6high cells (Figure 9B) and the mean level of pS6 
(Supplementary Figure S6A) was reduced in all sites. 
Some inter-site variations were observed, where the lung, 
spinal cord and brain metastases generally harbored a 
larger fraction of pS6high melanoma cells than e.g. bone 
metastases or s.c. tumors (Figure 9A, 9B), but this 
difference has not been further explored. We chose lung 
metastases and subcutaneous tumors for further analysis 
by immunofluorescence and confirmed BRAFi-induced 
reduction in pS6 (Figure 9C). Interestingly, in the treated 
lung metastases, the remaining pS6high melanoma cells 
tend to localize at the tumor border next to the stroma 
(Figure 9C). In the treated s.c. tumors, the distribution 
of pS6high tumor cells was more random, with less 
pronounced localization at the tumor-stroma interface 
(Figure 9C). Collectively, the in vivo data indicates that 
pS6high melanoma cells remain after BRAFi treatment in 
different metastatic sites, and e.g. in the lung they tend to 
localize close to the stroma.
Inhibitors of mTOR or PI3K reduces the 
protective influence of the fibroblasts in vitro
Based on the pS6 data, we hypothesized that 
mTORC1, or it activating pathways, might contribute to 
fibroblast-mediated protection from BRAFi. To test this 
hypothesis we employed an mTOR inhibitor, everolimus 
(mTORi) in combination with the BRAFi and compared 
the response in the mono-cultures versus the co-cultures 
with fibroblasts. We showed that mTORi+BRAFi 
treatment of the co-cultures eradicates a subpopulation 
of pS6high melanoma cells (Figure 10A, insert). 
Consequently, the melanoma cell survival in the co-
cultures was significantly reduced after mTORi+BRAFi 
compared to BRAFi alone. Thus, the survival benefit 
that we saw in the co-cultures treated with BRAFi alone 
was eliminated (Melmet 5) or significantly diminished 
(HM8) after co-administration of mTORi (Figure 
10A). A similar potentiation of the drug effect in the 
Figure 8: Immunofluorescence analysis of pS6 in asymmetric co-cultures. HM8 melanoma cells and fibroblasts were first 
cultured within adjacent compartments and subsequently allowed to interact (illustrated by arrows), forming asymmetric co-cultures before 
treatment with 1 μM BRAFi for 24 h (controls were not treated). The cultures were immunostained for pS6 (red) and GFP (green); cell 
nuclei were stained with DAPI. The staining patterns for the areas representing the distant site (labeled as “1”) and interaction front” 
(labeled as “2”) are shown. Scale bar, 200 μm.
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co-cultures was observed when BRAFi was combined 
with a pan-PI3K inhibitor, LY294002 (PI3Ki) (Figure 
10B). It should be noted that mTORi/PI3Ki also affected 
fibroblasts, reducing their number by ~25% (data not 
shown). To compensate for this effect, the number of 
fibroblasts was increased by 25% in the co-cultures 
where mTORi/PI3Ki was applied. Thereby, we can 
exclude the possibility that the potentiated effects in 
the co-cultures might be due to fewer fibroblasts. It is 
interesting to note that the effect of the single agents, 
mTORi or PI3Ki, was stronger in the co-cultures than 
the mono-cultures of Melmet 5, suggesting that the co-
cultured cells might be more dependent on PI3K-mTOR 
signaling.
Figure 9: Analysis of pS6 in melanoma cells from distinct sites in vivo. Melmet 5 melanoma cells were allowed to grow in 
distinct organs in mice with/without treatment with BRAFi. The metastatic organs and s.c. tumors were collected and analyzed by flow 
cytometry (A, B) or immunofluorescence (C). A. Representative dot-plots showing pS6 levels in Melmet 5 cells from non-treated (blue) and 
treated (black) animal organs. The pS6high melanoma cell subpopulations are indicated in red boxes. B. The bars indicate average percentage 
of pS6high cells ± SEM (n=3/4), except for the brain samples, where average ± St.Dev. (n=2) is shown. C. Immunofluorescence for pS6 
(red) and GFP (green) in s.c. tumors (upper panels) and lung metastases (lower panels; S, stromal region; T, tumor region) derived from 
non-treated and BRAFi treated animals. The pictures show an overlay of pS6 and GFP. Scale bar, 200μm.
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Re-activation of MAPK was suggested by others 
to be involved in fibroblast-mediated BRAFi resistance 
[11], and MAPK can also activate mTORC1 [29]. 
Therefore, we also tested BRAFi in combination with 
other inhibitors of the MAPK pathway. In our models, 
an ERK inhibitor, SCH772984 (ERKi), in combination 
with BRAFi did not eliminate a subpopulation of pS6high 
melanoma cell, neither potentiated the treatment effect 
in the co-cultures (Figure 11A). Likewise, no therapeutic 
benefit in the co-cultures was observed when BRAFi 
was combined with a MEK inhibitor (MEKi), MEK162 
(Figure 11B). Thus, the co-cultures demonstrated 
significantly higher cell survival/growth than the mono-
cultures after treatment with MEKi or ERKi alone or 
together with BRAFi.
Collectively, these results indicate that inhibition 
of PI3K-mTOR, but not other targets within the MAPK-
pathway, reduces the protective effect of the stroma and 
helps to eliminate melanoma cells that become refractory 
to BRAFi.
Inhibition of mTOR enhanced the antitumor-
effect in BRAFi-treated lung metastases in vivo
Aiming to explore the mTORi+BRAFi combination 
in vivo, we performed a pilot study and showed that by co-
treatment with mTORi, we further reduced pS6 levels/pS6high 
subpopulations compared to BRAFi alone (Supplementary 
Figure S6B). We concluded that the tested dose of mTORi 
acts on its molecular target, S6, in vivo. In further in vivo 
studies, we compared treatment efficacies on early-stage 
metastatic lesions established in mouse lung. Melmet 5 
cells were delivered to the lung through tail vein injection 
and were allowed to grow for 6 days before initiating the 
treatment with a vehicle (control), BRAFi, mTORi or the 
combination mTORi+ BRAFi. The tumor burden was scored 
by live imaging in vivo tracking bioluminescence. At 6 days 
post-injection, the metastatic lesions started to be detectable, 
but were still small (as judged from the bioluminescence, 
Figure 12B), and presumably rich in tumor-stroma contacts. 
Exposure of such lesions to the mTORi+BRAFi combination 
Figure 10: mTOR or PI3K inhibitor reduces the protective influence of fibroblasts in the co-cultures. Melanoma cells 
were grown as mono-cultures or co-cultures with fibroblasts and treated with 0.5 μM BRAFi (A, B), 5 nM mTORi (A), 10 μM PI3Ki (B) 
or the combination as indicated (A, B). The level of pS6 in the co-cultures was analyzed after 24 h by flow cytometry (histogram inserts). 
Melanoma cell survival/growth was scored after 72 h by measuring bioluminescence and relating the signal in the treated cells to the signal 
in the non-treated controls (set to 100); average ± SEM (n=3). *, p<0.05 (unpaired t-test).
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for 12 days inhibited metastatic growth. In contrast, 
metastases treated with the single agents, BRAFi or mTORi 
continued growing like the controls (Figure 12A, 12B and 
Supplementary Figure S7). Although the metastatic growth 
was resumed after the combined treatment was stopped, the 
temporal suppression of the tumor development supports the 
idea that active mTORC1 contributes to cell proliferation in 
a part of a BRAFi-treated tumor. Thus, co-suppression of 
mTOR and BRAF activity might be beneficial in early-stage 
metastases with abundant stromal contacts.
DISCUSSION
Adaptive and less frequently observed innate 
resistance to MAPK pathway inhibitors (MAPKi) is a well-
known problem in the clinical management of malignant 
melanoma. In the present study, we have revealed a 
mechanism of stroma-promoted resistance. Stromal cells, 
such as lung fibroblast, reduced melanoma sensitivity to 
BRAF inhibition through proximity-dependent interactions. 
The protective influence of the stroma might have significant 
implications for MAPK targeted therapies, since it can lead 
to emergence of non-responding cancer cell subpopulations 
in an otherwise well-responding tumor.
Consistent with previous reports [27, 31], we 
identified one of the mTORC1 substrates, pS6, as a 
marker discriminating BRAFi responders from non-
responders, and demonstrated its association with the 
protective influence of the stroma. Eradication of pS6high 
melanoma cells by co-targeting mTOR, potentiated an 
anti-cancer effect in the BRAFi-treated melanoma models 
with abundant stromal contacts. Thus, BRAFi-treated 
cancer cells with sustained pS6 levels might represent 
subpopulations that got a survival advantage from adjacent 
stroma. It is tempting to propose that the therapeutic 
benefit that we see in vivo after co-inhibition of BRAF 
and mTOR is due to co-targeting stroma-independent and 
stroma-dependent counterparts of metastases. The fact that 
we observe such a benefit in early-stage metastatic lesions, 
where stromal contacts are abundant, supports but does 
not prove this scenario. Although we primarily focused on 
suppressing mTOR to overcome stromal protection, our 
in vitro data indicates an equally good effect with PI3K 
inhibitors. Given that in some cases mTOR inhibition can 
lead to undesirable activation of AKT [23], targeting the 
upstream kinases, like PI3K, is an attractive alternative. 
Multiple clinical trials are now initiated to evaluate the 
benefit of co-inhibition of MAPK and mTOR or PI3K 
(https://clinicaltrials.gov/ct2/show/NCT01596140) [35]. 
Figure 11: ERK or MEK inhibitor does not eliminate the protective influence of fibroblasts in the co-cultures. Melanoma 
cells were grown as mono-cultures or co-cultures with fibroblasts and treated with 0.5 μM BRAFi (A, B), 10 nM ERKi (A), 0.5 μM 
MEKi (B) or the combination as indicated (A, B). The level of pS6 in the co-cultures was analyzed after 24 h treatment by flow cytometry 
(histogram inserts). Melanoma cell survival/growth was scored after 72 h by measuring bioluminescence and relating the signal in the 
treated cells to the signal in the non-treated controls (set to 100). Data indicates average ± SEM (n=5 in A), or ± St. Dev. (from three 
parallels in a single experiment in B). *, p<0.05 (unpaired t-test).
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Figure 12: Treatment effect on lung metastases in vivo. Melmet 5 cells were injected into mice i.v. and were allowed to grow for 
6 days before initiation of the treatment with a vehicle (control), 50 mg/kg BRAFi, 5 mg/kg mTORi or a combination of both drugs every 
weekday until day 17, when the treatment was stopped. Tumor burden was scored at days 6 (start), 17 (finish) and 38 (post-treatment) by 
live imaging in vivo, measuring bioluminescence (p/s/cm2/sr) in the IVIS Spectrum instrument. A. The bioluminescence signal at days 17 
and 38 was normalized to the signal at day 6 (for the non-normalized data, see Supplementary Figure S7). The number of animals per group 
is indicated in the legend. *, p<0.05 (unpaired t-test). B. Representative IVIS pictures showing the animals at the start and the end of the 
treatment.
Their rationale, though, does not lean specifically on 
stroma-facilitated resistance to MAPKi.
The protective effect of stroma could be explained 
by stroma-induced phenotype transition in the adjacent 
melanoma cells. We showed that in the presence of 
fibroblasts, melanoma cells acquired a de-differentiated 
mesenchymal-like phenotype. Such a phenotype has been 
linked to BRAFi resistance in several previous studies, 
where it was described as a cell-autonomous mechanism 
of resistance [24, 26, 36]. We show that this phenotype 
can be induced by extrinsic signals from the stroma. This 
phenotype displayed reduced sensitivity not only to BRAFi, 
but also MEKi, ERKi or combinations of these, as was also 
shown by others, but not in a tumor-stroma context [24, 26]. 
The fact that resistance was observed even though pERK 
was suppressed, raised doubts about MAPK dependence 
in this phenotype [24, 26]. In contrast, the sensitivity to 
PI3K/mTOR inhibition was preserved or even enhanced, 
suggesting that the stroma-induced phenotype might prefer 
PI3K/mTOR signaling. By switching to the mesenchymal 
phenotype, melanoma cells gained additional “tools” to 
signal via PI3K, e.g. up-regulated receptor-tyrosine kinases 
(RTKs) like Axl and PDGFRB or ECM fibronectin [26, 37]. 
Re-wiring of signaling towards the PI3K pathway was also 
reported for epithelial cancer cells that undergo EMT and 
acquire alternative RTKs [38]. In line with our observations, 
several recent studies showed that stroma-promoted 
BRAFi resistance involves the PI3K pathway [37, 39]. In 
contrast, Hirata et al. [11] demonstrated stroma-dependent 
re-activation of ERK as a resistance mechanism, which we 
could not confirm, since no therapeutic benefit after co-
administration of MEKi or ERKi was seen in our co-cultures. 
Collectively, this favors BRAFi combinations with RTK/
PI3K/mTOR inhibitors rather than MEK/ERK inhibitors 
in situations where a mesenchymal phenotype is promoted, 
e.g. tumors with abundant stroma. However, more profound 
analysis on MAPK is needed to clarify whether/how this 
pathway is implicated in the stroma-induced phenotype.
The majority of previous studies linked stroma-
induced BRAFi resistance to stroma-derived growth 
factors [3, 8, 37], which could act on distant cancer cells. 
This contradicts our and Hirata et al.’s [11] observations 
on the importance of close proximity between the tumor 
and the stromal cells. Based on our data, we propose that 
a tumor-stroma interaction front might be a site where 
BRAFi resistant melanoma cells reside, which remains 
to be validated in clinical material. Adjacent stromal 
cells could deposit ECM to which melanoma cells 
could attach and gain a survival advantage, as shown 
by others [11, 12]. Direct cell-cell communication via 
e.g. gap junctions could be another mechanism for how 
adjacent cancer cells might gain drug-resistance [9, 
10]. Although we observed stroma-induced enrichment 
for the ECM component fibronectin and a gap junction 
constituent Connexin-43, we have not yet explored their 
significance.
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In conclusion, we have shown that under the 
influence of adjacent fibroblasts, melanoma cells acquire 
a mesenchymal-like phenotype with enhanced resistance 
to MAPKi. This resistance could be overcome by co-
inhibiting PI3K/mTOR signaling. Understanding the link 
between stroma-induced mesenchymal transition and 
alterations in signaling should uncover nodes for targeting 
stroma-protected cancer cells. Thereby, BRAFi combination 
therapies could be designed to target both stroma-dependent 
and independent counterparts of metastases.
MATERIALS AND METHODS
Cell lines and drugs
Malignant melanoma cell lines: Melmet 5 (derived 
from lymph node metastases), HM8 and HM19 (both 
derived from brain metastases), were established from 
melanoma patients at the Oslo University Hospital, 
The Norwegian Radium hospital (Oslo, Norway) as 
described previously [40] (REK No: S-01252; 2.2007.997; 
2011/2183). Patient-3-pre cell line (derived from lymph 
node metastases [41]) was generously provided by Prof. 
Peter Hersey (University of Sydney, Sydney, Australia). 
All melanoma cells were transduced with lentivirus, 
carrying a human ferritin promoter-driven GFP-Luc 
construct described previously [42] (kindly provided by 
Dr. Glenn Merlino, NIH, MD). Human lung fibroblasts 
WI-38 were obtained from the ATCC (Rockville, MD). 
Human primary umbilical vein endothelial cells (HUVEC) 
and human monocyte cell line THP-1 were provided by 
Prof. Guttorm Haraldsen (Oslo University Hospital, 
Norway; REK S-05152) and Prof. Rigmor Solberg 
(University of Oslo, Norway), respectively.
All melanoma cell lines were cultured in RPMI 
1640 medium, supplemented with 10% fetal calf serum 
(FCS) and 2 mM L-Alanyl L-Glutamine (all from Sigma-
Aldrich, St. Louis, MO). The culture medium for THP-1 was 
additionally supplemented with 0.05 mM 2-mercaptoethanol 
(Sigma-Aldrich). WI-38 fibroblasts were cultured in EMEM 
medium (ATCC, Manassas, VA) supplemented with 10% 
FCS. HUVECs were cultured in MCDB131 medium (Gibco, 
Paisley, UK) supplemented with 7.5% FCS, 2 mM L-Alanyl 
L-Glutamine, 20 mM Hepes, 100 units/ml penicillin and 100 
g/ml streptomycin, 1 μg/ml hydrocortisone (all from Sigma-
Aldrich), 10 ng/ml EGF (R&D Systems, Minneapolis, 
MN) and 1 ng/ml bFGF (PeproTech, Rocky Hill, NJ). All 
cells cultures were maintained at 37°C in a humidified 
atmosphere containing 5% CO2 and were routinely tested 
for mycoplasma and cell ID.
Drugs
BRAFi vemurafenib and ERKi SCH772984 
were from Selleck Chemicals (Houston, TX), mTORi 
everolimus was from Novartis (Basel, Switzerland) 
and Sigma Aldrich, MEKi MEK162 was from 
MedChemExpress (Monmouth Junction, NJ), PI3Ki 
LY294002 was from Cell Signaling Technology 
(Danvers, MA). All drugs were dissolved in DMSO. For 
animal studies, the drugs were further diluted in 0.5% 
metylcellulose (Sigma-Aldrich).
Co-cultures and cultures in trans-well inserts
Co-cultures were prepared by seeding GFP-Luc-
labeled melanoma cells together with non-labeled stromal 
cells (WI-38, THP-1 or HUVEC) in the respective 
medium, at a ratio 1:4, and a total cell density up to 7 x 103 
cells/well in 96-well plates or 75 x 104 cells/T25 flasks. 
The same cell density was used for the mono-cultures.
To prepare asymmetric co-cultures, the melanoma 
cells and the fibroblast (20 x 103 each) were seeded in 
separated compartments within culture-inserts from Ibidi 
(Martinsried, Germany) placed on glass cover slips. After 
removing the inserts, the cells were cultured for 4 days 
allowing them to fill the gap and interact, before BRAFi was 
applied for 24 hours treatment (no BRAFi for controls).
To prepare cultures in trans-well inserts, 8 x 103 or 
20 x 104 melanoma cells were seeded out into 0.4 μm-pore 
membrane inserts in 24- or 6-well plates (Costar, Corning, 
NY), respectively. In the bottom wells, either fibroblasts 
or respective melanoma cells (for controls) were seeded, 
keeping the insert:bottom cell ratio at ~1:2.
For gene expression and protein analysis, the co-
cultures were pre-incubated for 48 hours followed by 24 
hours treatment with 1 μM BRAFi. Melanoma cells were 
separated from the fibroblasts by FACS, gating on the GFP 
signal and collecting only clearly GFP positive melanoma 
cells as shown in Supplementary Figure S8A. The mono-
cultures were handled identically. The purity of the FACS-
separated melanoma fractions (i.e. no contamination with 
fibroblasts) is guaranteed since the gating was stringent; 
no fibroblast-specific (female) transcripts were found in 
the melanoma (male) fractions; no descent in male-specific 
transcripts and luciferase (tag on melanoma) mRNA was 
detected.
Cell survival assays
Cell survival was evaluated either by measuring 
luciferase-generated bioluminescence or using the MTS 
assay. For the bioluminescence method, cells were 
grown/treated in white 96-well plates (Costar), and 
before measurement the culture medium was replaced 
with a fresh medium containing 0.1 mg/mL D-luciferin 
(Biosynth AG, Staad, Switzerland); after 10 min 
bioluminescence was measured by a plate reader (Victor2 
1420 Multilabel Counter, Perkin Elmer, Waltham, MA). 
For the MTS method, cells were grown in clear 96-well 
plates (Falcon, Durham, NC) or 24-well inserts (Costar). 
Before measurement, 20 μl of CellTiter 96®AQueous One 
solution (Promega, Madison, WI) was applied per each 
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100 μl medium, followed by ~1 h at 37°C incubation, and 
absorbance was measured at 490 nm by the plate reader.
Flow cytometry
Collected cells (from cultures or disintegrated tumor 
tissue) were fixed for 15 min in 1.6% paraformaldehyde 
(PFA) at room temperature (RT) and permeabilized 
with 100% ice cold methanol. Up to four samples 
were given a fluorescent “barcode” by adding pacific 
orange (PO) dye (Life Technologies, Carlsbad, CA) at 
different concentrations ranging from 0 to 2 ng/μl (see 
Supplementary Figure S8B). For the analysis of the in vivo 
samples, we also included a “spike” control (Melmet 5 
from in vitro), which received no PO (see Supplementary 
Figure S8C). After incubation at RT for 30 min, followed 
by washing, the barcoded samples were combined for 
simultaneous staining with antibodies against pS6-Alexa 
647 (Cell Signaling Technology, #4851 dilutions 1:80 for 
in vitro and 1:50 for in vivo samples), pERK-PE (Cell 
Signaling Technology, #5315; dilution 1:5) or Ki-67-PE 
(BD Biosciences, #556027; dilution 1:5) for 30 min at 
RT. For cell cycle analysis, pS6-Alexa 647 stained cells 
were additionally stained with 1.5 μg/ml Hoechst 33258 
(Life Technologies, #H3569) for 30 min at 37oC. The 
samples were analyzed on an LSR II flow cytometer (BD 
Bioscience, San Jose, CA). BD FACS DivaTM software 
was used to control the flow cytometer and Flow Jo 
software (FlowJo, Ashland, OR) was used to analyze the 
data.
Protein analysis
Protein lysates were prepared by re-suspending the 
cells in lysis buffer (150 mM NaCl, 50 mM Tris pH 7.5, 
0.1% Nonidet P40) containing protease- and phosphatase 
inhibitors (Roche Applied Science, Mannheim, Germany) 
followed by ultrasonication. For Western blotting, total 
cellular proteins (20 μg) were separated on NuPAGE® 
Novex 4-12% Bis-Tris Gel (Life Technologies). After 
transfer to a polyvinylidene difluoride membrane (Merck 
Millipore, Billerica, MA), it was blocked either with 10% 
BSA or 5% dry milk solution and incubated with primary 
antibodies at 4°C overnight, followed by incubation with 
secondary antibodies at RT for 1 h. After application of 
Super Signal West Dura kit solution (Thermo Scientific, 
Rockford, IL), the membrane was developed in a 
Syngene instrument (Syngene, Cambridge, UK) using the 
GeneSnap software.
The Simple Western immunoassay was performed 
on a PeggySue™ (ProteinSimple, San Jose, CA) applying 
0.4 μg total protein lysate and using the Size Separation 
Master Kit with Split Buffer (12-230 kDa) according to 
the manufacturer’s instructions. The Compass software 
(ProteinSimple, version 2.7.1) was used to program the 
PeggySue-machine and for quantification of the results.
The following antibodies from Cell Signaling 
Technology were used: anti-pS6 (#4858; 1:2000); anti-S6 
(#2217; 1:1000); anti-pERK (#4370, 1:2000), anti-ERK 
(#4695, 1:1000); anti-pAKT (#9271, 1:1000); anti-p-
mTOR (#5536, 1:50); anti-pGSK-3β (#9339, 1:50); anti-
MITF (#12590, 1:2000), anti-H3 (#4499, 1:2000) and 
anti-GAPDH (# 5174, 1:200). Mouse anti-AXL (used 
at 1:4000) was kindly provided by Prof. James Lorens 
(University of Bergen, Norway). Mouse anti-α-tubulin 
(Merck Millipore #CP06) was used at a dilution 1:5000.
The RPPA analysis on FACS-separated melanoma 
cells was performed at MD Anderson RPPA core facility 
(Houston, TX). In brief, denatured cell protein lysates 
were arrayed at serial dilutions on nitrocellulose-coated 
slides. Each slide was probed with a validated primary 
antibody (specified at the core facility’s home page; 
availbale upon request) followed by a biotin-conjugated 
secondary antibody; the signal was detected by a DAB 
colorimetric reaction. The slides were scaned and analyzed 
using a MicroVigene software (VigeneTech, Carliste, MA) 
to determine spot intensities. Each dilution curve was 
fitted with a logistic model (“Supercurve Fitting”). The 
data were log2-transformed and converted into standard 
scores by subtracting the mean of the whole screen and 
dividing by the standard deviation of the whole screen (for 
a given antibody).
Immunofluorescent staining (IF)
Cells seeded on coverslips were fixed for 15 min 
in 1.6% PFA at RT and permeabilized either with 100% 
ice cold methanol or 0.05% Saponin solution. Cells were 
stained with primary antibodies (rabbit anti-pERK, #4370, 
1:200 or rabbit anti-pS6, #2215, 1:200; both Cell Signaling 
Technology) in combination with goat anti-GFP (ab5450, 
1:2000, Abcam (Cambridge, UK)) overnight at 4°C, 
followed by 1 hour staining with secondary antibodies 
(donkey anti-rabbit DL549 and donkey anti-goat Alexa 
488) at RT and counterstained with DAPI (all from Life 
Technologies). Fluorescence images were taken using 
Zeiss LSM confocal microscope (Zeiss, Oberkochen, 
Germany) or inverse microscope Olympus IX8 (Olympus, 
Norway) and analyzed with ZEN 2009 Light Edition or 
Cell^P softwares, respectively.
Sections of paraffin embedded tumor tissue were 
deparaffinized with xylene and ethanol and boiled in 
antigen unmasking solution (1:100, Vector laboratories 
Inc, Burlingame, CA) for 15 min in a microwave. The 
slides were stained as above, except that anti-GFP was 
diluted 1:1000.
RNA isolation and q-PCR
Total RNA was isolated from the FACS-separated 
cell pellets using TRIzol® reagent (Life Technologies). 1 
μg RNA was reverse transcribed using cDNA Synthesis 
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Kit (Quanta Biosciences, Geithersburg, MD). q-PCR 
reaction was run in duplicates using 25 ng cDNA, mixed 
with 300 nM of each primer, 200 nM FAM-labeled probe 
(from the Universal Probe Library collection, Roche 
Applied Science) and 1x PerfeCTa q-PCR SuperMix 
(Quanta BioSciences) adjusted up to total volume of 25 
μL/well in 96-well plates (Bio-Rad, Hercules, CA). The 
PCR was performed using Bio-Rad CFX Connect™ Real 
Time PCR machine (Bio-Rad). Data was analyzed using 
Bio-Rad CFX Manager software.
Illumina microarray and data analysis
RNA was amplified from 500 ng total RNA using 
the Illumina® TotalPrepTM-96RNA amplification kit (Life 
Technologies) according to the manufacturer’s protocol. 
For each sample, 750 ng labeled cRNA was hybridized to 
Illumina Human HT-12v4 Expression BeadChip (Illumina, 
San Diego, CA). Hybridization was performed by the 
Norwegian Radium Hospital Microarray Core Facility 
according to Illumina protocols. The scanning was done 
with the iScan system. The data were annotated using 
the HumanHT-12_V4_0_R2_15002873_B.bgx file from 
Illumina. Sample data were quantile normalized and 
log2-transformed in Illumina GenomeStudio
® software. 
Preprocessed data was imported into J-Express v2012 
(www.molmine.com) where a multi-group ANOVA 
analysis was performed, followed by the application of 
principal component analysis (PCA) on the top ranked 
ANOVA-filtered genes to visualize differences between 
groups. Significance of Microarray (SAM) analysis was 
applied to identify differently expressed genes. Genes 
were considered significant if fold change FC ≥ 1.5 and a 
fold discovery rate FDR ≤ 1%. The microarray data have 
been deposited in NCBI’s Gene Expression Omnibus and 




To analyze pS6 levels, GFP-Luc-labeled Melmet 5 
cells were injected into athymic nude foxn1nu mice into 
the left ventricle (L.V) or subcutaneously (s.c.) (15 x 104 
or 1 x 106 cells/animal, respectively). After approximately 
one month, the animals were randomized before initiation 
of the treatment by oral gavage with BRAFi vemurafenib 
(50 mg/kg) or vehicle (DMSO/metylcellulose) twice/day, 
5 times in total. Where indicated, mTORi everolimus (5 
mg/mL) was applied in addition once/day. Animals were 
sacrificed 2 hours after the last treatment. Brain, lung, 
femur, spinal cord and subcutaneous tumors were collected 
and either disintegrated mechanically for analysis by flow 
cytometry, or formalin-fixed and paraffin-embedded for 
IF. For testing the treatment efficacy on early metastatic 
lesions, 75 x 104 GFP-Luc-labeled Melmet 5 cells were 
injected intravenously (i.v.) leading primarily to lung 
metastases. After 6 days, the animals were randomized 
and treated with either 50 mg/kg BRAFi vemurafenib, 
5 mg/kg mTORi everolimus, a combination of both 
drugs or vehicle every weekday for two weeks. Tumor 
growth was followed by reading bioluminescence (after 
intraperitoneally injection of 4mg D-Luciferin in 200 μL 
PBS) using an in vivo imaging system IVIS Spectrum 
(Perkin Elmer, Waltham, MA).
Statistical analysis
Two-tailed Student’s unpaired t-test was used 
in all statistical analysis. Differences were considered 
statistically significant if p-values were equal/below 0.05.
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